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Gemcitabine is currently the standard therapy for pancreatic cancer. However, growing concerns over gemcitabine resistance mean that
new combinatory therapies are required to prevent loss of efficacy with prolonged treatment. Here, we suggest that this could be achieved
through co-administration of RNA interference agents targeting the ubiquitin ligase ITCH. Stable anti-ITCH siRNA and shRNA
dendriplexes with a desirable safety profile were prepared using generation 3 poly(propylenimine) dendrimers (DAB-Am16). The complexes
were efficiently taken up by human pancreatic cancer cells and produced a 40-60% decrease in ITCH RNA and protein expression in vitro
(si/shRNA) and in a xenograft model of pancreatic cancer (shRNA). When co-administered with gemcitabine (100 mg/kg/week) at a
subtherapeutic dose, treatment with ITCH-shRNA (3x 50 mg/week) was able to fully suppress tumour growth for 17 days, suggesting that
downregulation of ITCH mediated by DAB-Am16/shRNA sensitizes pancreatic cancer to gemcitabine in an efficient and specific manner.
From the Clinical Editor: Gemcitabine delivery to pancreatic cancer often results in the common problem of drug resistance. This team
overcame the problem through co-administration of siRNA and shRNA dendriplexes targeting the ubiquitin ligase ITCH.
© 2015TheAuthors. Published byElsevier Inc. This is an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/3.0/).
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to rise to 12 million by 2030 [1]. For cancers such as pancreatic
cancer, 5-year survival rates are as low as 5% because of
diagnosis at an advanced stage [2]. Currently, treatment relies
mostly on systemic therapy using chemotherapeutic agents with
limited specificity. In advanced pancreatic cancer, the cytidine
analogue gemcitabine (2′2′-Difluoro-2′-deoxycytidine, GEM)
remains the standard course of treatment either in combination
with a number of other cytotoxic agents or as monotherapy for
patients with poor performance status [3,4].
Recently, molecular-targeted agents have shown considerable
potential. These type of agents can be highly specific which
potentially reduces side effects, but also limits their applicability to
patient populations pre-selected based on the molecular make-up
of the individual cancer [5]. As cancer agents are typically used in
combination to minimise the risk of drug resistance and dose
limiting toxicity, it would be desirable for any newly developed
therapy to work well in conjunction with other currently used
drugs. Novel forms of therapy that selectively sensitise cancer cellscle under the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-
ITCH RNAi chemotherapy booster for pancreatic cancer. Nanomedicine:
370 M. de la Fuente et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 369–377to the currently used cytotoxic agents would potentially fulfil these
requirements and combine improved efficacy, specificity and
reduced risk of resistance.
The exploitation of cancer specific molecular targets such as
HSP90 or Bcl-2 potentially offers an attractive strategy to improve
sensitivity and selectivity of conventional chemotherapeutic
agents [6,7]. Similarly, up-regulation of p73, a member of the
p53 family of transcription factors, sensitises cancer cells to a
variety of chemotherapeutic agents [8,9]. Both p73 and p53 are
thought to be involved in promoting apoptosis in response to
DNA damage [10]. Consequently, increased levels of these
molecules should sensitise cancer cells to cytotoxic drugs that
also trigger apoptosis. Although details of p73 regulation in
different cancers are still emerging, it is a promising target as, in
contrast to p53 (N50% mutation) it is rarely mutated [11].
Our group has previously shown that gene therapy using
expression of a minimal p53-derived apoptotic peptide can de-
repress p73, causing p73-mediated gene activation and tumour
regression [12]. RNAi has the ability to selectively switch off
certain genes at post-transcriptional level [13]. Here, we evaluate
interfering RNA (RNAi) targeting the p73 pathway as a chemo-
sensitisation strategy. This is achieved by reducing expression of
the ubiquitin ligase ITCH which controls p73 levels by ubiquitina-
tion and subsequent targeting to the proteasome for degradation. It
is hypothesised that down-regulation of this suppressor would
sensitise cells to chemotherapeutic agents and that RNAi based
therapy would act as a booster for conventional chemotherapeutic
agents [8,9].
In the current study we evaluate small-interfering (siRNA) or
short-hairpin RNA (shRNA) as mechanisms for down-regulation
and deliver these using a synthetic vector based on generation 3
polypropylenimine dendrimer (‘DAB-Am16’). We address the
question whether the DAB-Am16 vector system could deliver
RNAi based therapies to solid tumours at levels sufficient to allow
exploitation of the exquisite specificity of these agents in
combination with current anti-cancer agents for improved therapy
against challenging cancers such as pancreatic cancer.Methods
siRNA, shRNA and dendriplexes
siRNAs (i.e. anti-ITCH1 5’-3’: AAGTGCTTCTCAGAAT
GATGA; anti-ITCH2 5’-3: AACCACAACACACGAATTACA
at a ratio of 1:1; scrambled control sequence 5’-3’: GCAAACCAC
CAAUCUAACA; FITC-siRNA 5’-3’: AGGUAGUGUAAUCGC
CUUG-FITC, all Eurofins MWG Operon, Germany), shRNA
(pSUPER1198: CTGCCGCCGACAAATACA Oligoengine,
USA, or pSUPER.Mamm-X or a scrambled pSUPER1198
sequence non-specific control) were complexed with DAB-Am16
(Sigma-Aldrich, Dorset, UK) in 96-well plates by mixing equal
volumes (100 μL) of solutions of nucleic acid (shRNA or siRNA;
0.5 mg/mL in water) and DAB-Am16 (2.5 mg/mL, dextrose 5%
(w/v), pH adjusted to 9 for a degree of protonation (α) =0.4. Particle
size and zeta potential of the resulting dendriplexeswere determined
on a Nano-ZS Zetasizer (Malvern Instruments, Malvern, UK) at
room temperature. Transmission electron microscope (TEM)
imaging of particles occurred on a formvar resin-coated coppergrid counterstained with 1% uracil acid (FEI CM120, Biotwin,
Eindhoven, Netherlands). Stability of the dendriplexes was
evaluated both at 4 °C, under storage conditions and in simulated
biological medium at 37 °C.
Cell culture
Pancreatic cells MIA PaCa-2 and PANC-1 (DMEM, 10%FBS,
1% glutamine), HPAC (F12 Ham, 10% FBS, 1% L-glutamine,
1% non-essential amino acids, 2 μg/ml of insulin, 5 μg/ml
transferrin 10 ng/ml epidermal growth factor (EGF) and
40 ng/ml of hydrocortisone), and BxPC3 (RPMI-1640, 10%
FBS, 1% L-glutamine and 1 mM sodium pyruvate) were
obtained from ATCC or ECACC and grown at 37 °C under
5% CO2, 95% humidity. Cytotoxicity was measured as the IC50
using aMTT based assay 24 hours after the end of a 4 h incubation
with free and shRNA complexed DAB-Am16 [14].
Haemolysis assay
Freshmouse/rat erythrocyteswere centrifuged andwashedwith
PBS (1000 g, 10 min at 4 °C for 3 cycles) to produce a 3%
suspension which was incubated 1:1 with 5% dextrose containing
dendrimer or dendriplex concentrations at 37 °C for 4 hours.
Haemoglobin release in the supernatant was determined spectro-
photometrically (λ = 570 nm) and compared to negative (dextrose
5%) and positive controls (2% Triton X-100).
Cell uptake in pancreatic cell lines
The interaction of dendriplexes with cells seeded on
coverslips in 24-well plates was imaged using scanning
electron microscopy (SEM, FEI Quanta 200 F, Eindhoven,
NL) after treatment with DAB-Am16/shSCR (1 μg shRNA/
well) and fixation in paraformaldehyde (4% in PBS).
Fluorescent dendriplexes (siRNA-FITC or shRNA-Cy3, Mirus
Bio LLC, USA) were observed by confocal laser scanning
microscopy (CLSM, Leica TCS SP2, Leica Microsystems, UK)
after 4 h of incubation and fixation as above. Uptake of
dendriplexes with siRNA-FITC was quantified on a LSRII flow
cytometer (BDBiosciences, Oxford,UK) and FlowJo software (BD
Biosciences) in unfixed cells after 4 h incubation.
ITCH downregulation
Cells were transfected in 24-well plates with DAB-Am16/
shRNA (5 μg shRNA/well in 200 μL of FBS supplemented cell
culture medium) or Lipofectamine®2000 as per manufacturer’s
protocol (Life Technologies, Pasely, UK). After 48 h RNA was
extracted using the RNeasy Mini Kit (Qiagen, Hilden,
Germany). cDNA was synthesised using the QuantiTect
Reverse Transcription kit. QPCR reactions (10 μl of sam-
ple + 15-μL of a PCR-master-mix (QuantiTect SYBR Green
PCR kit, Qiagen) used the primer pairs (ITCH QuantiTect
Primer Assay) or GAPDH-forward (GGCAGTGATGGCTG-
GACTG) and reverse (CGGGAAGCTTGTGATCA ATGG)
primers. mRNA levels were evaluated for the target gene
(ITCH) and normalised against a reference gene (GAPDH). The
cycling conditions were 95 °C for 15 minutes DNA polymerase
activation followed by 40 cycles (15” at 94 °C, 30” at 55 °C
and 30” at 72 °C) followed by 10 mins at 72 °C. Melting curves
371M. de la Fuente et al / Nanomedicine: Nanotechnology, Biology, and Medicine 11 (2015) 369–377were performed in a range between 65 and 90 °C (data not
shown). For mRNA quantification, the ampification efficiency
(E) of the target and control genes for each of the transfected
conditions was calculated from the slope of a calibration curve
established at cDNA concentrations ranging from 10 pg to
1000 ng (E = 10−1/(slope)). The ratio (R) of the number of cDNA
target molecules over the number of cDNA reference molecules
(GAPDH) was calculated as
R ¼ E
−Ct;target
E−Ct;reference
:
ITCH protein in vitro
Harvested cells (trypsin-EDTA) were repeatedly washed
(Dulbecco’s PBS) and then lysed (4 °C, 1 h) in RIPA buffer
(Sigma-Aldrich) supplemented with phosphatase and protease
inhibitor cocktails (Pierce, Thermo Fisher Scientific). Supernatant
lysate (15,000 g for 15 min) protein content was assayed using the
BCA assay (Pierce). Typically, samples of 30 μg protein were
separated by SDS-PAGE (NuPage, Invitrogen; 4-12% poly
(acrylamide); 200 V for 50 min) then transferred onto a
nitrocellulose membrane (Invitrogen). Blocked membranes (5%
non-fat dry milk dispersion prepared in PBS containing 0.1%
Tween 20)were incubated (2 h at room temperature or overnight at
4 °C) with primary anti-ITCH antibody (611199, BDBiosciences)
or Actin antibody (ACTN05 C4; Abcam, Cambridge, UK), and
after five wash steps, for 1 h with the secondary antibody
conjugated with horseradish peroxidase (Invitrogen). After 5
washes, blots were developed with SuperSignal west pico
chemiluminescent detection kit (Pierce).
In vivo studies
Experimental work was carried out in accordance with local
ethics board and UK Home Office regulations and recommen-
dations of UKCCCR where applicable [15]. Dose ranging pilot
studies in mice female (CD-1, Harlan Laboratories, Derby, UK
or Balb-c Charles River Laboratories Intl, Margate UK) and
Sprague-Dawley rats (Harlan Laboratories). Animals were dosed
with DAB-Am16 equivalent (mg/kg) in dextrose 5% (w/v)
(pH 9 (α = 0.4) or 11 (α =0.1). Body weight and behaviour
were recorded [16]. In the absence of symptoms the dose was
increased step-wise. The effects of repeat administration and
combination regimes were then evaluated at the highest safe
single dose level. For tumour studies pancreatic tumour cells
(5x106) dispersed in 50% growth media/50% Matrigel® (BD
Bioscences) were subcutaneously injected in the left flanks of
each mouse (100 μL/flank, Swiss nude mice, Charles River).
Tumour growth was quantified by serial calliper measurements,
body weights were recorded and tumour volumes were
calculated (V = πd3/6).
ITCH tumour down-regulation
Excised MIA PaCa-2 xenograft tumours were stored in
RNAlater® at -80 °C. Tumours were homogenised on ice
in 1 mL of lysis buffer containing β-mercaptoethanol using
a Polytron® homogeniser (PT MR2100, Kinematica AG,Switzerland) and RNA extracted (Absolutely RNAMiniprep Kit,
Agilent, Workingham, UK). Statistical analysis was performed
usingOrigin 6.0. using a two-sample t-test; p b 0.1was considered
statistically significant.
Antitumour activity of a combined therapy based on shRNA
dendriplexes and GEM in mice bearing MIA PaCa-2 xenografts
Established MIA PaCa-2 tumours (≃75 mm3) were treated
with cycles consisting of one IV injection of shRNA dendriplexes
(2 mg/kg shRNA; 10 mg/kg DAB-Am16) every other day (days 1,
3 and 5 of a treatment cycle), and GEM (100 mg/kg, i.p.) on day 7
followed by a break of seven days. After statistical analysis of the
logarithmic transformed data (two-way analysis of variance,
followed by Bonferroni ad-hoc test) values of p b 0.05 (*),
p b 0.01 (**) and p b 0.001 (***) were considered statistically
significant (Prism5.0, Graph Pad Software Inc., La Jolla, CA,USA).Results
DAB-Am16 dendrimer forms colloidally stable complexes
with siRNA and shRNA which can be stabilised further
after protein binding.
Creation of stable dendriplexes with a small hydrodynamic
diameter requires careful control of the protonation stage by
keeping the pH of the dendrimer solution between 6 and 9
(α between 0.8 and 0.4) [17]. We hypothesised that a pH of 9
would strike an adequate balance between the strength of the
electrostatic interaction and the potential toxicity of the cationic
groups. At this pH, the ionised primary amino groups (pKa 10) at
the periphery will be exclusively responsible for complexation
with the anionic agents [18]. Under these conditions small
positively charged complexes (Figure 1,A) with low polydispersity
could be formed with shRNA (133 ± 3 nm, PDI 0.2, ζ 24 ±
5 mV) or siRNA (111 ± 4 nm, PDI 0.2, ζ 27 ± 4 mV). At 4 °C,
after an initial size increase (20 nm over 48 hours), the shRNA
complexes remain stable with low PDI for at least 14 days while
the siRNA particles continue to grow to reach an average diameter
of 370 nm. This reduced stability was mirrored by the increased
polydispersity observed for the siRNA complexes (Figure 1, A).
While the morphology of the complexes appears similar,
these results suggest RNAi molecular weight (shRNA 3176 bp;
siRNA 21 bp) to be a key factor in determining stability. The
rigidity or length of the nucleic acid may affect complex
compactness or change the ability for nucleic acids to bridge
particles as shown for inter-polyelectrolyte complexes [19,20].
To evaluate colloidal stability under conditions more represen-
tative of physiological environments, the more stable shRNA
complexes were further exposed to media containing salt and
proteins to simulate in vitro (plain and FBS-supplemented MEM)
and in vivo (plain and FBS-supplemented PBS) conditions
(Figure 1, B). Exposure to high ionic strength isotonic solutions,
in the absence of proteins, resulted in a 4 to 5-fold increase in size
after only 5 minutes. This effect could be linked to modulation of
the dendrimer-nucleic acid electrostatic interactions after charge
neutralisation [21,22] or loss of screening of repulsive electrostatic
interactions between particles [23]. Interestingly, the presence of
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Figure 1. Stability and toxicity of siRNA and shRNA dendriplexes. (A) The
hydrodynamic mean size and polydispersity of DAB-Am16 complexed with
siRNA (21 bp) or shRNA (3176 bp) was evaluated over time at 4 °C. Insert
images show TEM of complexes (Left: ▪ shRNA, right: • siRNA). (B)
Comparison of the colloidal stability of shRNA dendriplexes in physiological
buffers (MEM and PBS) without (grey columns) and with FBS-supplementation
(dashed columns). (C) Haemolytic activity of DAB-Am16 at pH 11 (α = 0.1;
closed circles), pH 9 (α =0.4; closed triangle) and of DAB-Am16/shSCR
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both media. This process would most likely occur in the same
fashion on injection in vivo with serum proteins rapidly coatingthese non-stealth cationic particles after systemic administration
[17]. Interactions with serum proteins frequently destroy complexes
i.e. when partial coating of the particles accelerates aggregation
through a bridging mechanism [24,25]. In contrast, total coating of
the particles can actually stabilise particles under physiological
conditions [26]. Our data suggest the interaction of proteins with
DAB-Am16 dendriplexes leads to a rapid and complete stabilising
coating which may play a role in the in vivo efficacy of these
dendriplexes after intravenous administration andmay play a role in
their highly specific distribution [27].
DAB-Am16 complexes efficiently transfect human pancreatic
cancer cells
The internalisation of RNAi-based dendriplexes was visua-
lised by SEM (Figure 2, A) showing localised membrane pit
formation suggestive of uptake along an endocytotic pathway.
Consistent with this are the observations following the
internalisation using CSLM (Figure 2, B). The fluorescent
siRNA can be observed in the cytoplasm and perinuclear areas.
By contrast shRNA, can be detected in the cytoplasm and
nucleus. These studies thus confirm qualitatively the delivery of
the nucleic acid cargo to the relevant intracellular compartment.
Current evidence suggests the specific pathway (e.g. pinocytosis,
clathrin-dependent or clathrin-independent/caveolae-mediated)
may depend on the transfection agent and cell lines and may
affect transfection efficiency [28]. Caveolae and clathrin
mediated endocytosis have been shown for polyamidoamine
(PAMAM) dendriplexes [29] the latter correlated with higher
silencing activity [30]. Dendriplex internalisation was further
quantified by flow cytometry, confirming that DAB-Am16
dendrimers were able to deliver the associated siRNA efficiently
to a high proportion of cells in all pancreatic cell lines (Figure 2,
C). In fact, the dendrimer system was significantly more
effective at delivering siRNA (80%) than the commercial
Lipofectamine® 2000 (20-25%).
Efficient anti-ITCH RNAi down-regulation of target gene
expression in pancreatic cancer cells
The previous results demonstrate effective delivery of
plasmid- and siRNA-based nucleic acids into cells. In order to
established whether these systems were equally suited to achieve
downregulation of the target genes their down-regulation of the
target gene ITCH was quantified in pancreatic cancer cells (MIA
PaCa-2) at the protein and gene expression level (Figure 3, A and
B) demonstrating an ITCH knock-down of 40-60%. Taken as a
whole, these results confirmed DAB-Am16 dendrimers to be
successful transfecting agents in pancreatic cells for both types of
RNAi agents. Based on the fact that better long-term colloidal
stability and the evidence for the prolonged duration of silencing
effects reported for shRNA [31] we chose to utilise shRNA as the
basis for our RNAi ITCH downregulation approach.
The safety of DAB-Am16 depends on protonation state,
complexation and dose
Earlier studies have demonstrated that biocompatibility could be
a cause for concern for transfection agents such as the DAB-Am16
dendrimer [32]. To test the hypothesis that free dendrimer rather
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free DAB-Am16 (solution) was compared to that of DAB-Am16
complexes with scrambled shRNA. The IC50 of DAB-Am16 is
cell-type dependent, ranging from the least sensitive BxPC-3 cells
(0.14 mg mL-1) to the most sensitiveMIA PaCa-2 cells (2 μg/mL)
(Table S1). Importantly, equivalent concentrations of dendrimer
were less toxic by two to three orders of magnitude, when given in
the formof nucleic acid complexes. In order to test the link betweendendrimer toxicity and the presence of cationic groups interaction
with murine erythrocytes was compared at a protonation states of
α = 0.1 and α = 0.4 (Figure 1, C). At pH 11 the dendrimer has
little protonation (α = 0.1) making it 5x less haemolytic than at
pH 9 (α = 0.4). These results are in line with the IC50 values
obtained; the reduction in toxicity can be attributed to the
reduction in the number of free cationic groups available to
interact with the anionic erythrocytes membrane after
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downregulation inMIA PaCa-2 cells. Western blot showing ITCH protein levels
48 h after transfection with DAB-Am16 dendriplexes (80 μg siRNA or shRNA)
carrying scrambled (SCR) or ITCH targeted (ITCH) RNAi. B) ITCH mRNA
levels in MIA PaCa-2 cells 72 h after anti-ITCH RNAi treatment. Cells were
transfected with DAB-Am16 complexed with a control (SCR) or ITCH-targeted
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ITCH in MIA PaCa-2 tumour xenografts. Tumour-bearing mice received an IV
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dendriplexes (10 mg/kg dendrimer eq. dose) on day 1, 3 and 5. Data represent
mean ± SEM of three replicates. * p b 0.1.
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tion of DAB-Am16 also reduces the number of available
cationic charges and reduces haemolytic activity by almost an
order of magnitude, again. Erythrocytes could be incubated with
dendriplexes at concentrations up to 1.25 mg/mL before any
haemolytic activity was observed. Interestingly, up to a concen-
tration ca. 1 mg/mL, dendrimers at pH 11 showed lowerhaemolytic activity when incubated with rat, rather than murine,
erythrocytes, highlighting interspecies differences in toxicological
evaluations (Supplemental Figure 1).
Based on haemocompatibility and a projected 10-fold dilution
after IV injection, free DAB-Am16 was administered at a starting
dose of 10 mg/kg in a pilot study. In mice, dendrimer toxicity, as a
single IV bolus, was found to be dose and pH dependent confirming
the predictive value of some of the in vitro studies (data not shown).
Free DAB-Am16 was well tolerated at doses up to 30 mg/kg when
administered as a 3 mg/mL solution (pH 9).An increase of the pH to
11 allowed the administration of doses up to 30 mg/kg without
toxicity. On the other hand, a slight dilution of the dendrimer (from
4 mg/mL to 2.5 mg/mL) and a slow rate of injectionwithout altering
the pH, did not improve tolerability, confirming the importance of
controlling ionisation. Encouragingly, repeated daily administrations
of the free dendrimer at a dose of 10 mg/kg over 5 days (cumulative
dose of 50 mg/kg) did not result in significant weight loss and
clinical signs of toxicity were not observed. In rats, free DAB-Am16
could be safely administered at doses up to 40 mg/kg. This
finding also correlates well with the haemocompatibility results
(Supplemental Figure 1) where rat erythrocytes were shown to
better resist the action of the dendrimers confirming the
importance of species differences. To allow the use of relevant
human pancreatic tumour cell lines as the disease model we
proceeded to use mice for further studies.
Finally, the safety of combination of shRNA dendriplexes with
GEM was evaluated. GEM currently constitutes the first line of
treatment for pancreatic cancer [3]. Typical regimes involve GEM
therapy in combination with paclitaxel, erlotinib, capecitabine or
cisplatin. In patients with poor performance status, monotherapy is
typically given to minimize the potentially detrimental side effects
associated with more aggressive treatment regimes. GEM (up to
1000 mg/m2) is given as a cycle consisting of weekly 30-minute
infusions spread over three weeks. In our study, GEM was
administered weekly as a single IP injection of a 50 mg/kg or
100 mg/kg dose. Based on dose ranging studies, a treatment
schedule for the shRNAcombination therapywas devised consisting
of three IV administrations of dendriplexes on alternate days (days 1,
3 and 5) with GEM following on day 7. Co-administration of GEM
with the dendriplexes (day 1) or between DAB-Am16/shRNA
injections (day 2) proved toxic but interestingly, the combination
was well tolerated even over several cycles when the initial dose of
GEM was administered on day 7, irrespective of the GEM dose.
DAB-Am16/shRNA reduces expression of ITCH target protein
in pancreatic tumour xenografts
The ability of DAB-Am16 dendrimers to deliver an ITCH-
targeted shRNA to pancreatic tumours and for the shRNA to affect
an effective down-regulation of the ITCH target gene was studied
inmice bearingMIAPaCa-2 xenografts (Figure 3). To this end, the
dendriplexeswere administered on alternate days for three days at a
dose equivalent to 10 mg/kg of DAB-Am16. Intratumoural ITCH
mRNA levels were determined on day 6, i.e. 24 h after the last
dendriplex injection, and revealed 40% decreased mRNA levels
compared to tumours treated with the scrambled control shRNA
(Figure 3, C). Given the fact that the harvested tumour contains a
range of non-cancer cells, e.g. vascular and connective tissue, this
value is very consistent with the effects observed in the pancreatic
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treated with GEM (open square, 100 mg/kg, days 7 and 21), and GEM in
combination with DAB-Am16/shSCR (inverted closed triangle, 10 mg/kg
DAB-Am16 and 2 mg/kg shSCR, on days 1, 3, 5, 15, 17, 19), or
Gemcintabine in combination with DAB-Am16/shITCH (closed triangle,
10 mg/kg DAB-Am16 and 2 mg/kg shITCH, days 1, 3, 5, 15, 17, 19). (B)
Body weight of mice served as a surrogate marker of toxicity and was
recorded throughout the experiment. Saline treated animals were used as
control. Graphic represents mean ± SEM (n = 4). Statistical differences are
represented as * (p b 0. 5), ** (p b 0.05), and *** (p b 0.001).
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relatively efficient process.
DAB-Am16/shRNA in combination with GEM efficiently slows
pancreatic tumour progression
In order to test whether the levels of downregulation observed
could potentially improve therapeutic outcome in pancreatic
cancer, the RNAi therapy was evaluated in combination with
GEM (Figure 4). Mice carrying established MIA PaCa-2
xenograft tumours (N5 mm ø) were treated with two cycles of
a combination of anti-ITCH shRNA dendriplexes (10 mg/kg
DAB-Am16 and 2 mg/kg shRNA on day 1, 3, 5) and GEM
(100 mg/kg, day 7).
GEM, an anti-metabolite drug of the nucleoside-analogue
type, is frequently used in advanced pancreatic cancer because it
is well tolerated [3]. GEM, when administered alone at a dose of
100 mg/kg, had no significant impact on tumour growth in our
model, allowing tumours to reach more than 10-times the startingvolume within 24 days (Figure 4, A). Similar results have been
reported for GEM in MIA PaCa-2 models at a similar dose, and
improved efficacy has been previously reported in combination
with other therapeutic agents, including nucleoside analogues
[34], flavonoids [35] or co-treatment with monoclonal antibodies
and radiation [36].
p53, is a tumour suppressor gene involved with the induction of
cancer cell apoptosis in response to chemotherapy. However, more
than 50% of cancers have been shown to have disabled this
pathway and in pancreatic cancers the rate of p53 mutations could
be as high as 70% [37]. In contrast, the pro-apoptotic protein p73 is
rarely mutated and potentially offers a functional alternative [38]
that we have previously shown can be exploited therapeutically
[12]. Here we have chosen to test whether down-regulation of
ITCH, an E3 ubiquitin ligase that targets the pro-apoptotic protein
p73 for degradation could be used to sensitize pancreatic cancers to
conventional chemotherapeutic agents.
While the combination of GEM and scrambled shRNA
dendriplexes has some effect, this was significant (p b 0.5) only
on day 27 (Figure 4, A). This observation is not entirely
surprising as an inhibitory effect of DAB-Am16 on the growth of
some tumours has been previously reported [39].
In contrast, the combination of the ITCH-targeted shRNA
dendriplexes andGEMcaused a highly significant delay (p b 0.001)
in tumour growth, apparent from the second treatment cycle
(Figure 4, A). While the tumours of untreated animals and those on
GEM monotherapy or scrambled shRNA/GEM combination
therapy progressed within a week, the animals treated with the
ITCH shRNA/GEM combination showed stable disease for
17 days. The untreated tumours grow 14-fold in volume within
four weeks compared to the animals treated with the ITCH shRNA/
GEM combination, which only doubled in size. Importantly, the
treatment was very well tolerated with no significant differences in
body weight observed between treatment groups (Figure 4, B). The
combination of lack of toxicity and high efficaciousness suggests
that the downregulation of ITCH does indeed lead to a tumour-
specific sensitisation to GEM, which by itself does not exhibit
activity against this pancreatic tumour.Discussion
The promise of RNAi for cancer treatment has led to the
development and subsequent clinical evaluation of a variety of
agents providing proof-of-principle for this form of therapy [40].
Still, efficient systemic delivery remains a major obstacle,
preventing wider use of RNAi-based therapies, in particular for
therapy of advanced cancer [41]. Encapsulation of RNAi agents in
nano-sized vectors by complexation of the anionic nucleic acids to
an excess of cationic linear, branched or dendritic polymers is a
promising strategy for delivery of genetic therapies [42,43]. The
generation 3 poly(propylenimine) dendrimers (DAB-Am16) offer
a balance between safety and high transfection efficiency in vitro
and in vivo [32,39]. While the polymer has previously been used
for TNFa based cancer gene therapywewanted to explore whether
these systems could also be effective for RNAi based therapies.We
were able to demonstrate that the toxicity of DAB-Am16 is closely
linked to its protonation state and that complexation with nucleic
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orders of magnitude. These observations also hold true for the in
vivo administration of the system. We report that DAB-Am 16
dendrimers form colloidally stable complexes with siRNA and
shRNA which are efficiently taken up by endocytotic mechanisms
into a range of human pancreas cancer cell lines. The dendriplexes
based on siRNA and shRNA achieve effective downregulation of
the ITCH target RNA and protein expression in vitro and in a
xenograft model of pancreatic cancer (shRNA).
In combination with a therapeutically ineffective dose of GEM
(100 mg/kg/week) the ITCH-RNAi treatment (3x 50 mg/week)
was able to fully suppress tumour growth for 17 days.
Drug resistance poses a significant clinical challenge, which
chemosensitisation strategies aim to address. Cancer resistance
mechanisms can be categorized into predominantly pharmacody-
namic or pharmacokinetic, i.e. mechanisms that reduce the ability
to engage the cancer cell’s downstream response (typically
apoptosis), or those, which reduce the exposure of the cellular
target to the drug (e.g. increased metabolism or efflux pumps etc.)
[44]. In pancreatic cancer cells a number of putative pharmaco-
dynamic (e.g. HMAGA1, MUC4, HIF1a, HSP27, c-Scr, c-Met)
and pharmacokinetic resistance mechanisms (e.g. hENT1, cDK)
have been identified, however, their clinical relevance has not been
confirmed in all cases [44]. The clinical evidence suggests reduced
GEM transport and exposure as important factors in drug
resistance in pancreatic cancer. Barriers to drug transport develop
due to pathological features of the neo-vasculature, the stroma and
cellular transport proteins; for example, cellular expression of the
transport related proteins hENT1 and cDK has been shown to lead
to increased patient survival [45]while reduced transport measured
using biomarkers has been shown to predict resistance [46].
The use of RNAi therapies that target drug resistance related
molecular targets potentially allows a highly specific interventions
and chemosensitisation. In lung cancer, RNAi strategies targeting
c-myc [47], polo-like kinase I (PLK1, [48]), and ribonuclotide
reductase subunit 1 (RRM1, [49]) have shown sensitisation of
tumours to GEM.
Re-setting of the cellular apoptotic balance, which has been
well-established as the mechanism of action of RNAi mediated
ITCH downregulation [8,9,50], would lead to a sensitization of
the affected pancreatic cancer cells in a wider range of
circumstances. Our observations demonstrate that a combination
of GEM with anti-ITCH RNAi can lead to good control of
tumour growth in conditions of suboptimal drug exposure,
irrespective of whether they are caused by pharmacokinetic or
pharmacodynamic mechanisms (Figure 4). Our data suggest this
approach could provide an elegant and specific way to increase
the efficacy of conventional anti-cancer drugs that would fit well
with the current therapeutic approaches to treatment of advanced
pancreatic cancer, for which GEM, either alone or in
combination with other cytotoxic agents/and or radiotherapy, is
currently the treatment of choice [3].Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.nano.2014.09.010.References
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